^
No biomarker
CLL
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1wk
BCR-ABL1 fusion
ALL
ponatinib
Sensitive
:
A1
Int J Hematol - 1wk
CRLF2 rearrangement
ALL
ruxolitinib
Sensitive
:
C2
Leukemia - 1wk
No biomarker
AML
azacitidine oral
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
venetoclax
Sensitive
:
A1
Roche Press Release - 2wk
IDH2 mutation + SRSF2 mutation
AML
venetoclax
Sensitive
:
C3
Blood Adv - 2wk
NRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
KRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
No biomarker
CML
bosutinib
Sensitive
:
A2
Int J Hematol - 3wk
FLT3-ITD mutation
AML
quizartinib
Sensitive
:
C2
Haematologica - 3wk
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive
:
A1
FLT3 mutation
AML
gilteritinib
Sensitive
:
A1
IDH2 mutation
AML
enasidenib
Sensitive
:
A1
No biomarker
AML
glasdegib
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
CLL
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
AML
cytarabine/daunorubicin liposomal formulation
Sensitive
:
A1
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
BCR-ABL1 fusion
CML
dasatinib
Sensitive
:
A1
No biomarker
CLL
ICP-022
Sensitive
:
A1
FLT3 mutation
AML
midostaurin
Sensitive
:
A1
CD33 positive
AML
gemtuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
ALL
imatinib
Sensitive
:
A1
No biomarker
CML
omacetaxine mepesuccinate
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
CD20 expression
CLL
rituximab-arrx
Sensitive
:
A1
BCR-ABL1 T315I
CML
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
ALL
ponatinib
Sensitive
:
A1
No biomarker
ALL
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our